Paradigm Asset Management Co. LLC Sells 1,200 Shares of Pfizer Inc. (NYSE:PFE)

Paradigm Asset Management Co. LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,033 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the period. Paradigm Asset Management Co. LLC’s holdings in Pfizer were worth $1,325,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Wealthspire Advisors LLC raised its stake in shares of Pfizer by 21.4% in the third quarter. Wealthspire Advisors LLC now owns 150,164 shares of the biopharmaceutical company’s stock valued at $4,981,000 after acquiring an additional 26,455 shares during the last quarter. Cape Investment Advisory Inc. raised its position in Pfizer by 102.6% in the 3rd quarter. Cape Investment Advisory Inc. now owns 8,144 shares of the biopharmaceutical company’s stock worth $270,000 after purchasing an additional 4,124 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Pfizer by 8.4% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,253,987 shares of the biopharmaceutical company’s stock worth $174,275,000 after purchasing an additional 405,581 shares during the last quarter. Flynn Zito Capital Management LLC raised its position in Pfizer by 7.4% in the 3rd quarter. Flynn Zito Capital Management LLC now owns 20,353 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 1,411 shares during the last quarter. Finally, Cornerstone Wealth Management LLC raised its position in Pfizer by 2.0% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 65,788 shares of the biopharmaceutical company’s stock worth $2,182,000 after purchasing an additional 1,297 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7 %

NYSE:PFE traded up $0.19 on Monday, hitting $28.88. 22,589,100 shares of the company’s stock were exchanged, compared to its average volume of 42,365,793. The firm has a 50-day moving average price of $27.27 and a 200-day moving average price of $27.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a market cap of $163.65 billion, a P/E ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.82%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.